Bausch+Lomb Results Presentation Deck
Reconciliation of Reported Revenue to Constant Currency Revenue¹ and
Constant Currency Revenue Growth¹ ($M)
Contact Lens
Consumer²
Surgical Consumables
Surgical Implantables
Surgical Equipment
Lumify
Ocuvite + PreserVision
Artelac
Premium IOLS
Vyzulta
Contact Lens (excluding impact of
distribution facility disruptions)
International Pharmaceuticals²
Surgical Implantables* excluding
Eye Cee One IOL
BAUSCH+ LOMB
Calculation of Constant Currency Revenue for the Three Months Ended
September 30, 2023
September 30, 2022
Revenue as
Reported
228
420
93
45
47
44
104
30
13
19
233
70
45
Changes in
Exchange Rates³
4
9
(1)
(1)
(1)
(1)
1
4
(1)
Constant
Currency
Revenue (Non-
GAAP)¹
232
429
92
44
46
44
104
30
12
20
237
70
44
Revenue as
Reported
67
Change in
Reported Revenue
40
Amount
Pct.
222
6
3%
375
45
12%
85
8
9%
45
0%
42
5
12%
30
14
47%
m
98
6
6%
27
3
11%
9
4
44%
13
6
46%
222
11
5%
3
4%
5
Change in
Constant Currency Revenue ¹
13%
Amount
10
54
7
(1)
4
14
6
3
3
7
15
3
4
Pct.
5%
14%
8%
-2%
10%
47%
6%
11%
33%
54%
7%
4%
10%
1. This is a non-GAAP measure or non-GAAP ratio. See Slide 1 and this Appendix for further information on non-GAAP measures and ratios.
2. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the
reported results of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar
products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.
3. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the
monthly average currency exchange rates during the comparable prior period.
4. As of the first quarter of 2023, certain products were recategorized across the consumables, implantables and equipment product categories. This change was made as management believes this better aligns these products in their
respective categories. Prior period presentations of product categories have been conformed to current product category structure to allow investors to evaluate results between periods on a consistent basis.
5. Contact Lens Revenue Impact of distribution facility disruptions is approximately $5M.
33View entire presentation